A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00578825 |
Recruitment Status : Unknown
Verified August 2013 by Hospital Authority, Hong Kong.
Recruitment status was: Not yet recruiting
First Posted : December 21, 2007
Last Update Posted : August 22, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Severe Acute Respiratory Syndrome | Drug: Lopinavir / Ritonavir plus Ribavirin | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 340 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome |

- Development of severe SARS [ Time Frame: Any time during the acute illness ]
- Adverse events [ Time Frame: Throughout the illness period ]
- SARS-CoV Viral load [ Time Frame: Throughout the illness period ]
- Immunological profile [ Time Frame: Throughout the illness period ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Male or female over the age of 18 with a diagnosis of SARS and with valid consent will be recruited.
Exclusion Criteria:
- Subjects with medical conditions that makes the prescription of study medications unsafe are excluded.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00578825
Contact: Wai Cho Yu, Dr | (852) 2990 3737 | yuwc@ha.org.hk |
China | |
Department of Health | |
Hong Kong, China | |
Sub-Investigator: Wilina Lim, Dr | |
Kowloon Hospital | |
Hong Kong, China | |
Sub-Investigator: Thomas Mok, Dr | |
Prince of Wales Hospital | |
Hong Kong, China | |
Princess Margaret Hospital | |
Hong Kong, China | |
Sub-Investigator: ST Lai, Dr | |
Sub-Investigator: KL Au, Dr | |
Queen Mary Hospital | |
Hong Kong, China | |
The Chinese University of Hong Kong | |
Hong Kong, China | |
Sub-Investigator: Dennis Lo, Prof | |
Sub-Investigator: Christopher Lam, Prof | |
Sub-Investigator: David Hui, Prof | |
The University of Hong Kong | |
Hong Kong, China | |
Sub-Investigator: Malik Peiris, Prof | |
Sub-Investigator: Kenneth Tsang, Prof | |
Sub-Investigator: KY Yuen, Prof | |
Tuen Mun Hospital | |
Hong Kong, China | |
United Christian Hospital | |
Hong Kong, China |
Principal Investigator: | Wai Cho Yu, Dr | Department of Medicine & Geriatrics, Princess Margaret Hospital |
ClinicalTrials.gov Identifier: | NCT00578825 |
Other Study ID Numbers: |
KW/FR/04-009 HARECCTR0500028 NTWC/CREC/349/05 |
First Posted: | December 21, 2007 Key Record Dates |
Last Update Posted: | August 22, 2013 |
Last Verified: | August 2013 |
Severe acute respiratory syndrome |
Severe Acute Respiratory Syndrome Syndrome Disease Pathologic Processes Respiratory Tract Infections Infections Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Virus Diseases Respiratory Tract Diseases Ritonavir Lopinavir |
Ribavirin HIV Protease Inhibitors Viral Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Antimetabolites |